{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:02:33Z","timestamp":1782824553951,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009031","name":"Japan Agency for Medical Research and Development Department of Industrial Academic Collaboration","doi-asserted-by":"publisher","award":["19ek0510023h0003"],"award-info":[{"award-number":["19ek0510023h0003"]}],"id":[{"id":"10.13039\/501100009031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jtct.2022.09.021","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T02:06:16Z","timestamp":1664330776000},"page":"847.e1-847.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Acute Promyelocytic Leukemia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9775","authenticated-orcid":false,"given":"Masamitsu","family":"Yanada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-1710","authenticated-orcid":false,"given":"Haruko","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3395","authenticated-orcid":false,"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0032-6994","authenticated-orcid":false,"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.09.021_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0003","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0004","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2005.03.127","article-title":"Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group","volume":"23","author":"de Botton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0006","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12185-008-0020-8","article-title":"Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group","volume":"87","author":"Kohno","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0007","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2009.07.010","article-title":"Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen","volume":"15","author":"Thirugnanam","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0008","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2012-11-466862","article-title":"Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia","volume":"121","author":"Yanada","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0009","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/cas.12230","article-title":"Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97","volume":"104","author":"Fujita","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtct.2022.09.021_bib0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2014.03.025","article-title":"Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission","volume":"20","author":"Holter Chakrabarty","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0011","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/leu.2015.12","article-title":"Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet","volume":"29","author":"Lengfelder","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.09.021_bib0012","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/bmt.2016.96","article-title":"Autologous transplant remains the preferred therapy for relapsed APL in CR2","volume":"51","author":"Ganzel","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0013","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/10428194.2016.1231406","article-title":"Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide","volume":"58","author":"Yanada","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.09.021_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12185-019-02759-y","article-title":"Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan","volume":"111","author":"Yanada","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0015","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41409-020-01162-0","article-title":"Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission","volume":"56","author":"Sanz","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0016","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.17221","article-title":"Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens","volume":"192","author":"Fouzia","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41409-021-01501-9","article-title":"Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis","volume":"57","author":"Yanada","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0021","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0022","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10428194.2017.1357173","article-title":"Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients","volume":"59","author":"Yanada","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.09.021_bib0023","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0024","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0025","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","article-title":"Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients","volume":"94","author":"Niu","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0026","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0027","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1532\/IJH97.05044","article-title":"Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies","volume":"82","author":"Shigeno","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0028","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2003.01.149","article-title":"Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia","volume":"21","author":"Raffoux","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0029","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2018-05-851824","article-title":"Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial","volume":"132","author":"Russell","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0030","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00277-018-3400-z","article-title":"Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy","volume":"97","author":"Cicconi","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.09.021_bib0031","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/cam4.2883","article-title":"A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide","volume":"9","author":"Kulkarni","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.09.021_bib0032","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clml.2013.02.023","article-title":"Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Pemmaraju","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.09.021_bib0033","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41409-021-01247-4","article-title":"The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia","volume":"56","author":"Yanada","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0034","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.021_bib0035","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease","volume":"23","author":"Kurosawa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.021_bib0036","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722016591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722016591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:05:48Z","timestamp":1763003148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722016591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666636722016591"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.09.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Acute Promyelocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}